Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
As earlier has been communicated an extra general meeting (EGM) in ChronTech Pharma AB (the Company) on the 19th of April 2013 resolved to accept that a group of shareholders acquire a percentage of approximately 70 per cent of the Company’s projects regarding development of DNA vaccines against hepatitis B and hepatitis C.
Help employers find you! Check out all the jobs and post your resume.
